Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Tuesday, January 24, 2017

Using the National Institutes of Health Stroke Scale A Cautionary Tale

The NIH Stroke Scale Has Limited Utility in Accurate Daily Monitoring of Neurologic Status

And yet it is constantly used, even with limited objectivity.
Patrick Lyden
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.


The National Institutes of Health Stroke Scale (NIHSS) is the most widely used deficit rating scale in modern neurology: over 500 000 healthcare professionals have been certified to administer it using a web-based platform. Every clinical trial in vascular neurology—prevention, acute treatment, recovery—requires a severity assessment, and the NIHSS became the gold standard for stroke severity rating after the first successful trial in acute stroke therapy, the NINDS r-tPA (National Institute of Neurological Disorders and Stroke recombinant tissue-type plasminogen activator) for Acute Stroke Trial (the Trial).1 As part of the Trial, detailed and rigorous training/certification procedures were created for the NIHSS that facilitate wider use of the scale outside of research.2
Today, payers and regulators demand reportable data on patient outcomes, and such outcomes must be adjusted for baseline severity: the NIHSS has become the de facto metric for regulatory compliance. The Joint Commission, as part of its certification program for Primary Stroke Centers, now requires an NIHSS score within 12 hours of admission for all stroke patients; this assessment is to be done by a certified examiner.3,4 Federal agencies also require outcomes adjusted for baseline stroke severity—using the NIHSS.5 Despite widening regulatory requirements, considerable problems may arise in using the NIHSS in clinical practice because the scale was designed for research purposes.6 Given that the scale was not designed for such widespread—and determinative—application, anyone using (or mandating use of) the NIHSS must understand its development history, clinimetric properties, and its proper bedside administration.


During the late 1980s, several stroke-deficit rating scales were in use.710 For use in a National Institutes of Health–sponsored trial of naloxone for acute stroke, investigators combined scales that had been developed at the University of Cincinnati, Canadian neurological scale, the Edinburgh-2 coma scale, and the Oxbury …
View Full Text

No comments:

Post a Comment